All studies | Studies in patients with high cardiovascular risk | |
---|---|---|
Total number of studies | 39 (100%) | 4 (100%) |
No. of patients in all studies | 4992 | 1230 |
Publication year, median (range) | 1996 (1974–2014) | 2013 (1992–2014) |
Publication year <2000 | 24 (62%) | 1 (25%) |
Multicentre studies | 9 (23%) | 0 (0%) |
Study size, median (IQR) | 84 (54–129) | 251 (210–406) |
Patient age, median (IQR) | 54 (51–61) | 66 (63–67) |
Male sex, median (IQR) | 62 (25–87) | 77 (66–88) |
Follow-up* | ||
0.5–1 year | 7 (18%) | 3 (75%) |
>1–3 years | 21 (54%) | 1 (25%) |
>3 years | 11 (28%) | 0 (0%) |
Colchicine treatment (mg/day) | ||
≤1 | 27 (69%) | 3 (75%) |
>1 | 12 (31%) | 1 (25%) |
Control treatment, n (%) | ||
Active treatment | 8 (21%) | 0 (0%) |
Inactive, placebo | 31 (79%) | 4 (100%) |
Clinical setting | ||
CVD, arteriosclerotic | 3 (8%) | 3 (75%) |
CVD, other | 1 (3%) | 1 (25%) |
Hepatobiliary disease | 25 (64%) | 0 (0%) |
Other | 10 (26%) | 0 (0%) |
Cardiovascular risk profile | ||
Primary prevention | 0 (0%) | 0 (0%) |
Secondary prevention | 4 (10%) | 4 (100%) |
Not specified | 35 (90%) | 0 (0%) |
Risk of bias (high, unclear, low) | ||
Randomisation | 3%/59%/38% | 0%/25%/75% |
Allocation concealment | 0%/72%/28% | 0%/75%/25% |
Blinding of patients and personnel | 18%/13%/69% | 25%/0%/75% |
Blinding of outcome assessment | 0%/79%/21% | 0%/25%/75% |
Incomplete outcome data | 41%/38%/21% | 0%/50%/50% |
Selective reporting | 13%/84%/3% | 0%/100%/0% |
Number of studies (% of column total) if not stated otherwise.
*Longest follow-up period for an outcome that was used in this systematic review.
CVD, cardiovascular disease.